Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS · Delayed Price · Currency is USD
27.73
0.00 (0.00%)
Oct 31, 2025, 4:00 PM EDT
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$628,950
Profits / Employee
$4,710
Market Cap
42.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Takeda Pharmaceutical Company News
- 2 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 3 days ago - Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Benzinga
- 3 days ago - Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9% - Nasdaq
- 3 days ago - Takeda Pharmaceutical Q2 25 Earnings Conference Call At 6:00 AM ET - Nasdaq
- 3 days ago - Takeda Pharmaceutical (TAK) Adjusts Financial Guidance for FY2025 - GuruFocus